CoChat
Sign Up
Cited by 66Tuberculosis Research and EpidemiologyImmune responses and vaccinationsImmunotherapy and Immune Responses

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis

Open access
Larsen, Sasha E., Erasmus, Jesse H., Reese, Valerie A., Pecor, Tiffany, Archer, Jacob, Kandahar, Amit, Hsu, Fan-Chi, Nicholes, Katrina +3 more·2023·Vaccines
DOI 10.3390/vaccines11010130PMC PMC9862644
Open this paper in CoChat — free accountOpen PDF

Abstract

Mycobacterium tuberculosis (M.tb), a bacterial pathogen that causes tuberculosis disease (TB), exerts an extensive burden on global health. The complex nature of M.tb, coupled with different TB disease stages, has made identifying immune correlates of protection challenging and subsequently slowing vaccine candidate progress. In this work, we leveraged two delivery platforms as prophylactic vaccines to assess immunity and subsequent efficacy against low-dose and ultra-low-dose aerosol challenges with M.tb H37Rv in C57BL/6 mice. Our second-generation TB vaccine candidate ID91 was produced as a fusion protein formulated with a synthetic TLR4 agonist (glucopyranosyl lipid adjuvant in a stable emulsion) or as a novel replicating-RNA (repRNA) formulated in a nanostructured lipid carrier. Protein subunit- and RNA-based vaccines preferentially elicit cellular immune responses to different ID91 epitopes. In a single prophylactic immunization screen, both platforms reduced pulmonary bacterial burden compared to the controls. Excitingly, in prime-boost strategies, the groups that received heterologous RNA-prime, protein-boost or combination immunizations demonstrated the greatest reduction in bacterial burden and a unique humoral and cellular immune response profile. These data are the first to report that repRNA platforms are a viable system for TB vaccines and should be pursued with high-priority M.tb antigens containing CD4+ and CD8+ T-cell epitopes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/vaccines11010130

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 62

  1. [4]Cucinotta D. Vanelli M. WHO Declares COVID-19 a Pandemic Acta Biomed. 2020 91 157 160 10.23750/abm.v91i1.9397 32191675 PMC7569573 · DOI
  2. [8]Zaman K. Tuberculosis: A global health problem J. Health Popul. Nutr. 2010 28 111 113 10.3329/jhpn.v28i2.4879 20411672 PMC2980871 · DOI
  3. [9]Mallapaty S. Callaway E. Kozlov M. Ledford H. Pickrell J. Van Noorden R. How COVID vaccines shaped 2021 in eight powerful charts Nature 2021 600 580 583 10.1038/d41586-021-03686-x 34916666 · DOI
  4. [10]Parveen U. Sultana S. Heba S.F. Rafi R. Begum A. Fatima N. Pretomanid: A novel therapeutic paradigm for treatment of drug resistant tuberculosis Indian J. Tuberc. 2021 68 106 113 10.1016/j.ijtb.2020.09.005 33641829 · DOI
  5. [11]Haldar R. Narayanan S.J. A novel ensemble based recommendation approach using network based analysis for identification of effective drugs for Tuberculosis Math. Biosci. Eng. 2022 19 873 891 10.3934/mbe.2022040 34903017 · DOI
  6. [12]Ahmed S. Nandi S. Saxena A.K. An updated patent review on drugs for the treatment of tuberculosis (2018-present) Expert Opin. Ther. Pat. 2022 32 401 421 10.1080/13543776.2022.2012151 34846976 · DOI
  7. [13]Almeida D. Converse P.J. Li S.-Y. Upton A.M. Fotouhi N. Nuermberger E.L. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis Antimicrob. Agents Chemother. 2021 65 e0141221 10.1128/AAC.01412-21 34570644 PMC8597756 · DOI
  8. [14]Larkins-Ford J. Greenstein T. Van N. Degefu Y.N. Olson M.C. Sokolov A. Aldridge B.B. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis Cell Syst. 2021 12 1046 1063.e1047 10.1016/j.cels.2021.08.004 34469743 PMC8617591 · DOI
  9. [15]Houben R.M.G.J. A Menzies N. Sumner T. Huynh G.H. Arinaminpathy N. Goldhaber-Fiebert J.D. Lin H.-H. Wu C.-Y. Mandal S. Pandey S. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: A combined analysis of 11 mathematical models Lancet Glob. Health 2016 4 e806 e815 10.1016/S2214-109X(16)30199-1 27720688 PMC6375908 · DOI
  10. [16]Menzies N. Gomez G.B. Bozzani F. Chatterjee S. Foster N. Baena I.G. Laurence Y.V. Qiang S. Siroka A. Sweeney S. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: A combined analysis of nine models Lancet Glob. Health 2016 4 e816 e826 10.1016/S2214-109X(16)30265-0 27720689 PMC5527122 · DOI
  11. [17]Arregui S. Iglesias M.J. Samper S. Marinova D. Martin C. Sanz J. Moreno Y. Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures Proc. Natl. Acad. Sci. USA 2018 115 E3238 E3245 10.1073/pnas.1720606115 29563223 PMC5889657 · DOI
  12. [18]Roy A. Eisenhut M. Harris R.J. Rodrigues L.C. Sridhar S. Habermann S. Snell L.B. Mangtani P. Adetifa I. Lalvani A. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: Systematic review and meta-analysis BMJ 2014 349 g4643 10.1136/bmj.g4643 25097193 PMC4122754 · DOI
  13. [19]Van Der Meeren O. Hatherill M. Nduba V. Wilkinson R.J. Muyoyeta M. Van Brakel E. Ayles H.M. Henostroza G. Thienemann F. Scriba T.J. Phase 2b Controlled Trial of M72/AS01(E) Vaccine to Prevent Tuberculosis N. Engl. J. Med. 2018 379 1621 1634 10.1056/NEJMoa1803484 30280651 PMC6151253 · DOI
  14. [20]Tait D.R. Hatherill M. Van Der Meeren O. Ginsberg A.M. Van Brakel E. Salaun B. Scriba T.J. Akite E.J. Ayles H.M. Bollaerts A. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis N. Engl. J. Med. 2019 381 2429 2439 10.1056/NEJMoa1909953 31661198 · DOI · Paper page
  15. [21]Martin C. Aguilo N. Marinova D. Gonzalo-Asensio J. Update on TB Vaccine Pipeline Appl. Sci. 2020 10 2632 10.3390/app10072632 · DOI
  16. [22]Lewinsohn D.A. Lewinsohn D.M. Scriba T.J. Polyfunctional CD4(+) T Cells as Targets for Tuberculosis Vaccination Front. Immunol. 2017 8 1262 10.3389/fimmu.2017.01262 29051764 PMC5633696 · DOI
  17. [23]Tameris M.D. Hatherill M. Landry B.S. Scriba T.J. Snowden M.A. Lockhart S. E Shea J. McClain J.B. Hussey G.D. A Hanekom W. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial Lancet 2013 381 1021 1028 10.1016/S0140-6736(13)60177-4 23391465 PMC5424647 · DOI
  18. [24]Lu L.L. Smith M.T. Yu K.K.Q. Luedemann C. Suscovich T.J. Grace P.S. Cain A. Yu W.H. McKitrick T.R. Lauffenburger D. IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure Nat. Med. 2019 25 977 987 10.1038/s41591-019-0441-3 31110348 PMC6559862 · DOI
  19. [25]Smith C.M. Proulx M.K. Lai R. Kiritsy M.C. Bell T.A. Hock P. de Villena F.P.-M. Ferris M.T. Baker R.E. Behar S.M. Functionally Overlapping Variants Control Tuberculosis Susceptibility in Collaborative Cross Mice mBio 2019 10 e02791-19 10.1128/mBio.02791-19 31772048 PMC6879725 · DOI
  20. [26]Behar S.M. Antigen-specific CD8(+) T cells and protective immunity to tuberculosis Adv. Exp. Med. Biol. 2013 783 141 163 10.1007/978-1-4614-6111-1_8 23468108 PMC5784412 · DOI
  21. [27]Behar S.M. Woodworth J.S. Wu Y. Next generation: Tuberculosis vaccines that elicit protective CD8+ T cells Expert Rev. Vaccines 2007 6 441 456 10.1586/14760584.6.3.441 17542758 PMC3134449 · DOI
  22. [28]Boom W.H. New TB vaccines: Is there a requirement for CD8 T cells? J. Clin. Investig. 2007 117 2092 2094 10.1172/JCI32933 17671648 PMC1934597 · DOI
  23. [29]Lazarevic V. Flynn J. CD8+ T cells in tuberculosis Am. J. Respir. Crit. Care Med. 2002 166 1116 1121 10.1164/rccm.2204027 12379557 · DOI
  24. [30]Lewinsohn D.A. Swarbrick G.M. Park B. Cansler M.E. Null M.D. Toren K.G. Baseke J. Zalwango S. Mayanja-Kizza H. Malone L.L. Comprehensive definition of human immunodominant CD8 antigens in tuberculosis Npj. Vaccines 2017 2 8 10.1038/s41541-017-0008-6 28775896 PMC5538316 · DOI
  25. [31]Lin P.L. Flynn J.L. CD8 T cells and Mycobacterium tuberculosis infection Semin. Immunopathol. 2015 37 239 249 10.1007/s00281-015-0490-8 25917388 PMC4439333 · DOI
  26. [32]Kamath A.B. Woodworth J. Xiong X. Taylor C. Weng Y. Behar S.M. Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection J. Exp. Med. 2004 200 1479 1489 10.1084/jem.20041690 15557351 PMC2211947 · DOI
  27. [33]Jeyanathan M. Mu J. McCormick S. Damjanovic D. Small C.-L. Shaler C.R. Kugathasan K. Xing Z. Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment Am. J. Respir. Crit. Care Med. 2010 181 862 872 10.1164/rccm.200910-1583OC 20019338 · DOI
  28. [34]Smith S.M. Klein M.R. Malin A.S. Sillah J. Huygen K. Andersen P. McAdam K.P.W.J. Dockrell H.M. Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia Infect. Immun. 2000 68 7144 7148 10.1128/IAI.68.12.7144-7148.2000 11083843 PMC97828 · DOI
  29. [35]Tascon R.E. Stavropoulos E. Lukacs K.V. Colston M.J. Protection against Mycobacterium tuberculosis infection by CD8+ T cells requires the production of gamma interferon Infect. Immun. 1998 66 830 834 10.1128/IAI.66.2.830-834.1998 9453650 PMC107978 · DOI
  30. [36]Müller I. Cobbold S.P. Waldmann H. Kaufmann S.H. Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells Infect. Immun. 1987 55 2037 2041 10.1128/iai.55.9.2037-2041.1987 3114143 PMC260652 · DOI
  31. [37]Orme I.M. Collins F.M. Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin Cell. Immunol. 1984 84 113 120 10.1016/0008-8749(84)90082-0 6421492 · DOI
  32. [38]Flynn J.L. Chan J. Immunology of tuberculosis Annu. Rev. Immunol. 2001 19 93 129 10.1146/annurev.immunol.19.1.93 11244032 · DOI
  33. [39]Cho S. Mehra V. Thoma-Uszynski S. Stenger S. Serbina N. Mazzaccaro R.J. Flynn J.L. Barnes P.F. Southwood S. Celis E. Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis Proc. Natl. Acad. Sci. USA 2000 97 12210 12215 10.1073/pnas.210391497 11035787 PMC17320 · DOI
  34. [40]Serbina N.V. Liu C.C. Scanga C.A. Flynn J.L. CD8+ CTL from lungs of Mycobacterium tuberculosis-infected mice express perforin in vivo and lyse infected macrophages J. Immunol. 2000 165 353 363 10.4049/jimmunol.165.1.353 10861072 · DOI
  35. [41]Serbina N.V. Flynn J.L. CD8(+) T cells participate in the memory immune response to Mycobacterium tuberculosis Infect. Immun. 2001 69 4320 4328 10.1128/IAI.69.7.4320-4328.2001 11401969 PMC98502 · DOI
  36. [42]Brookes R.H. Pathan A.A. McShane H. Hensmann M. Price D.A. Hill A.V.S. CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages Eur. J. Immunol. 2003 33 3293 3302 10.1002/eji.200324109 14635037 · DOI
  37. [43]Wang J. Thorson L. Stokes R.W. Santosuosso M. Huygen K. Zganiacz A. Hitt M. Xing Z. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis J. Immunol. 2004 173 6357 6365 10.4049/jimmunol.173.10.6357 15528375 · DOI
  38. [44]Darrah P.A. Zeppa J.J. Maiello P. Hackney J.A. Ii M.H.W. Hughes T.K. Pokkali S. Ii P.A.S. Grant N.L. Rodgers M.A. Prevention of tuberculosis in macaques after intravenous BCG immunization Nature 2020 577 95 102 10.1038/s41586-019-1817-8 31894150 PMC7015856 · DOI
  39. [45]Roordink D. Williams A. Fritzell B. Laddy D.J. Gerdil E. Graffin A.M. Tait D. van der Pol L. van den Brink I. Holleman M. The TB vaccine development pathway—An innovative approach to accelerating global TB vaccine development Tuberculosis 2021 126 102040 10.1016/j.tube.2020.102040 33310626 PMC7896101 · DOI
  40. [46]Whitlow E. Mustafa A.S. Hanif S.N.M. An Overview of the Development of New Vaccines for Tuberculosis Vaccines 2020 8 586 10.3390/vaccines8040586 33027958 PMC7712106 · DOI
  41. [48]Xue T. Stavropoulos E. Yang M. Ragno S. Vordermeier M. Chambers M. Hewinson G. Lowrie D.B. Colston M.J. Tascon R.E. RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection Infect. Immun. 2004 72 6324 6329 10.1128/IAI.72.11.6324-6329.2004 15501761 PMC523008 · DOI · Paper page
  42. [49]Erasmus J.H. Khandhar A.P. Guderian J. Granger B. Archer J. Archer M. Gage E. Fuerte-Stone J. Larson E. Lin S. A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika Mol. Ther. 2018 26 2507 2522 10.1016/j.ymthe.2018.07.010 30078765 PMC6171036 · DOI · Paper page
  43. [51]Ljungberg K. Liljeström P. Self-replicating alphavirus RNA vaccines Expert Rev. Vaccines 2015 14 177 194 10.1586/14760584.2015.965690 25269775 · DOI
  44. [52]Leitner W.W. Hwang L.N. Deveer M.J. Zhou A. Silverman R.H. Williams B. Dubensky T.W. Ying H. Restifo N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways Nat. Med. 2003 9 33 39 10.1038/nm813 12496961 PMC1484510 · DOI
  45. [53]Bertholet S. Ireton G.C. Ordway D.J. Windish H.P. Pine S.O. Kahn M. Phan T. Orme I.M. Vedvick T.S. Baldwin S.L. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis Sci. Transl. Med. 2010 2 53ra74 10.1126/scitranslmed.3001094 20944089 PMC3110937 · DOI
  46. [54]Larsen S.E. Baldwin S.L. Orr M.T. Reese V.A. Pecor T. Granger B. Cauwelaert N.D. Podell B.K. Coler R.N. Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment Vaccines 2018 6 30 10.3390/vaccines6020030 29795025 PMC6027321 · DOI
  47. [55]Coler R.N. Bertholet S. Moutaftsi M. Guderian J.A. Windish H.P. Baldwin S.L. Laughlin E.M. Duthie M. Fox C. Carter D. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant PLoS ONE 2011 6 e16333 10.1371/journal.pone.0016333 21298114 PMC3027669 · DOI
  48. [56]Larsen S.E. Reese V.A. Pecor T. Berube B.J. Cooper S.K. Brewer G. Ordway D. Henao-Tamayo M. Podell B.K. Baldwin S.L. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models Sci. Rep. 2021 11 9040 10.1038/s41598-021-88291-8 33907221 PMC8079704 · DOI
  49. [57]Orr M.T. Ireton G.C. Beebe E.A. Huang P.-W.D. Reese V.A. Argilla D. Coler R.N. Reed S.G. Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis J. Immunol. 2014 193 2911 2918 10.4049/jimmunol.1401103 25086172 PMC4157111 · DOI
  50. [58]Bertholet S. Ireton G.C. Kahn M. Guderian J. Mohamath R. Stride N. Laughlin E.M. Baldwin S.L. Vedvick T.S. Coler R.N. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis J. Immunol. 2008 181 7948 7957 10.4049/jimmunol.181.11.7948 19017986 PMC2586986 · DOI
  51. [59]Orr M.T. Ireton G.C. Beebe E.A. Huang P.-W.D. Reese V.A. Argilla D. Coler R.N. Reed S.G. Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization J. Control. Release 2014 177 20 26 10.1016/j.jconrel.2013.12.025 24382398 PMC3956454 · DOI
  52. [60]Tian Y. da Silva Antunes R. Sidney J. Lindestam Arlehamn C.S. Grifoni A. Dhanda S.K. Paul S. Peters B. Weiskopf D. Sette A. A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models for Mycobacterium tuberculosis and Bordetella pertussis Front. Immunol. 2018 9 2778 10.3389/fimmu.2018.02778 30555469 PMC6281829 · DOI
  53. [61]Lindestam Arlehamn C.S. Lewinsohn D. Sette A. Lewinsohn D. Antigens for CD4 and CD8 T cells in tuberculosis Cold Spring Harb. Perspect. Med. 2014 4 a018465 10.1101/cshperspect.a018465 24852051 PMC4066646 · DOI
  54. [62]Gagneux S. Small P.M. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development Lancet Infect. Dis. 2007 7 328 337 10.1016/S1473-3099(07)70108-1 17448936 · DOI
  55. [63]Day T.A. Penn-Nicholson A. Luabeya A.K.K. Fiore-Gartland A. Du Plessis N. Loxton A.G. Vergara J. Rolf T.A. Reid T.D. Toefy A. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: A randomised, double-blind, placebo-controlled, phase 2a trial Lancet Respir. Med. 2020 9 373 386 10.1016/S2213-2600(20)30319-2 33306991 · DOI
  56. [64]Baldwin S.L. Ching L.K. Pine S.O. Moutaftsi M. Lucas E. Vallur A. Orr M.T. Bertholet S. Reed S.G. Coler R.N. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells J. Immunol. 2013 191 2514 2525 10.4049/jimmunol.1301161 23904160 PMC3791622 · DOI
  57. [65]Lu Y.-J. Barreira-Silva P. Boyce S. Powers J. Cavallo K. Behar S.M. CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection Cell Rep. 2021 36 109696 10.1016/j.celrep.2021.109696 34525366 PMC8466141 · DOI
  58. [66]Irvine E.B. O’Neil A. Darrah P.A. Shin S. Choudhary A. Li W. Honnen W. Mehra S. Kaushal D. Gideon H.P. Robust IgM responses following intravenous vaccination with Bacille Calmette-Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques Nat. Immunol. 2021 22 1515 1523 10.1038/s41590-021-01066-1 34811542 PMC8642241 · DOI
  59. [67]Orr M.T. Beebe E.A. Hudson T.E. Argilla D. Huang P.-W.D. Reese V.A. Fox C.B. Reed S.G. Coler R.N. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy Vaccine 2015 33 6570 6578 10.1016/j.vaccine.2015.10.115 26541135 PMC4679420 · DOI
  60. [68]Pilkington E.H. Suys E.J. Trevaskis N.L. Wheatley A.K. Zukancic D. Algarni A. Al-Wassiti H. Davis T.P. Pouton C.W. Kent S.J. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases Acta Biomater. 2021 131 16 40 10.1016/j.actbio.2021.06.023 34153512 PMC8272596 · DOI
  61. [69]Mulligan M.J. Lyke K.E. Kitchin N. Absalon J. Gurtman A. Lockhart S. Neuzil K. Raabe V. Bailey R. Swanson K.A. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Nature 2020 586 589 593 10.1038/s41586-020-2639-4 32785213 · DOI · Paper page
  62. [71]Anderson E.J. Rouphael N.G. Widge A.T. Jackson L.A. Roberts P.C. Makhene M. Chappell J.D. Denison M.R. Stevens L.J. Pruijssers A.J. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults N. Engl. J. Med. 2020 383 2427 2438 10.1056/NEJMoa2028436 32991794 PMC7556339 · DOI · Paper page

Cited by

Sorted by citations

Authors
Larsen, S. E., Erasmus, J. H., Reese, V. A., Pecor, T., Archer, J., Kandahar, A., Hsu, F.-C., Nicholes, K., Reed, S. G., Baldwin, S. L., & Coler, R. N.
Affiliations
  • Seattle Children's Research Institute (US)
  • University of Washington (US)
  • HDT BioCorp, Seattle, WA 98102, USA
  • Hematologics Inc., Seattle, WA 98121, USA
Corresponding author
Coler, Rhea N.
ORCID
Venue
Vaccines
Publisher
MDPI AG
Published
2023-01-05
Volume
11
Issue
1
Pages
130
ISSN
2076-393X (ISSN-L)
DOI
10.3390/vaccines11010130
PMC
PMC9862644
OpenAlex
W4313559172
Cited by
66
References
5
Citations by year
2026: 7 · 2025: 25 · 2024: 25 · 2023: 9
FWCI
12.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Vaccines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Allergy and Infectious Diseases (R01AI125160, MR/R005850/1, T32A1075090)
  • MRC (R01AI125160, MR/R005850/1, T32A1075090)
  • European Union (R01AI125160, MR/R005850/1, T32A1075090)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
Mycobacterium tuberculosis, tuberculosis vaccine, nanostructured lipid carriers, TLR4 agonist, prime-boost vaccination, aerosol challenge, CD4+ T cell epitopes, CTL epitopes, humoral and cellular immune response, prophylactic vaccination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review